Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2006119352) METHOD OF TREATING COGNITIVE DECLINE AND SYNAPTIC LOSS RELATED TO ALZHEIMER'S DISEASE
Latest bibliographic data on file with the International Bureau   

Pub. No.: WO/2006/119352 International Application No.: PCT/US2006/016964
Publication Date: 09.11.2006 International Filing Date: 03.05.2006
IPC:
A61K 35/12 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35
Medicinal preparations containing material or reaction products thereof with undetermined constitution
12
Materials from mammals or birds
Applicants:
ETHELL, Douglas [US/US]; US (UsOnly)
ARENDASH, Gary, W. [US/US]; US (UsOnly)
UNIVERSITY OF SOUTH FLORIDA [US/US]; 3702 Spectrum Blvd., Suite 155 Tampa, Florida 33612, US (AllExceptUS)
Inventors:
ETHELL, Douglas; US
ARENDASH, Gary, W.; US
Agent:
TONER, Thomas, E.; Smith & Hopen, P.A. 180 Pine Avenue North Oldsmar, Florida 34677, US
Priority Data:
60/677,18003.05.2005US
Title (EN) METHOD OF TREATING COGNITIVE DECLINE AND SYNAPTIC LOSS RELATED TO ALZHEIMER'S DISEASE
(FR) PROCEDE POUR TRAITER LE DECLIN COGNITIF ET LA PERTE SYNAPTIQUE LIES A LA MALADIE D'ALZHEIMER
Abstract:
(EN) A method treating a subject with Alzheimer's disease wherein A&bgr;-reactive immune cells, splenocytes and lymphocytes, are generated in vitro or in vivo, re-stimulated in vitro, and then adoptively transferred into the cognitively-impaired subject. The population of immune cells can be derived from a donor with a natural or adaptive immune response to A&bgr;, stimulated by exposure to A&bgr; in vivo. The donor cells are then collected and re-stimulated by subsequent exposure to A&bgr; in vitro prior to administration to the subject. Alternatively, the population of immune cells can be derived from the subject and then stimulated by exposure to A&bgr; in vitro.
(FR) L'invention concerne un procédé pour traiter un sujet souffrant de la maladie d'Alzheimer. Selon ce procédé, des cellules immunitaires sensibles à la bêta-amyloïde (Aß), des splénocytes et des lymphocytes, sont générées in vitro ou in vivo, restimulées in vitro, puis introduites, par transfert adoptif, dans le sujet dont la faculté cognitive a été altérée. La population de cellules immunitaires peut être dérivée d'un donneur qui présente une réponse immunitaire naturelle ou adaptative à la Aß, stimulée par une exposition à la Aß in vivo. Les cellules du donneur sont ensuite collectées et restimulées par exposition subséquente à la Aß in vitro, avant d'être administrées au sujet. Autre possibilité, la population de cellules immunitaires peut être dérivée du sujet, puis stimulée par exposition à la Aß in vitro.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (EPO) (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)